Opthea (ASX:OPT) says it has finalised the protocol study designs and key start-up activities in readiness for the initiation of the phase three ShORe and COAST pivotal clinical trials of OPT-302 in wet age-related macular degeneration. …
Opthea confirms plans and protocols for late-stage OPT-302 studies
February 24, 2021 Australian Biotech
Latest Video
New Stories
-
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News -
New Zealand's Pharmac announces a shift in treatment for blood cancer
April 9, 2026 - - Latest News -
It is imperative to very carefully read what the minister said, and then read it again
April 9, 2026 - - Latest News -
Stuart Dignam joins MTPConnect board as it embarks on its second decade
April 8, 2026 - - Latest News